|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Bria E et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2007;[Epub ahead of print]. Abstract
Gianni L et al. Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007;7(2):67-71. Abstract
Hooning MJ et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99(5):365-75. Abstract
Hunt S. Trastuzumab cardiotoxicity — A sleeping giant or a worthwhile tradeoff ? Presentation. ASCO 2007. No abstract available
Jones LW et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50(15):1435-41. Abstract
Jones LW et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 2007;16(5):1026-31. Abstract
Ng R, Green MD. Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin Drug Saf 2007;6(3):315-21. Abstract
Pinder MC et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25(25):3808-15. Abstract
Rastogi P et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs AC Twith trastuzumab (H). Proc ASCO 2007;Abstract LBA513.
Telli ML et al. Trastuzumab-related cardiotoxicity: Calling into question the concept ofreversibility. J Clin Oncol 2007;25(23):3525-33. Abstract
 |
 |
